ArticleInsights into imaging2025
Habitat radiomics assists radiologists in accurately diagnosing lymph node metastasis of adenocarcinoma of the esophagogastric junction.
Article in Insights into imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Habitat imaging based on enhanced CT for predicting occult central lymph node metastasis in papillary thyroid carcinoma.European radiology · 2026Article
- Integration of Node-RADS and Habitat Radiomics for Predicting Occult Nodal Metastasis in Bladder Cancer.Annals of surgical oncology · 2026Article
- Article
- Incremental diagnostic value of tumor habitat radiomics for risk stratification in thymic epithelial tumors.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
objectivesThis study aimed to develop a habitat radiomics (HR) model capable of preoperatively predicting lymph node metastasis (LNM) in adenocarcinoma of the esophagogastric junction (AEG) and to implement its use in clinical practice.
methodsIn this retrospective analysis, 337 patients from three centers were enrolled and divided into three cohorts: training, validation, and test (208, 52, and 77 patients, respectively). We constructed HR models, conventional radiomics models, and combined models to identify LNM in AEG. The area under the curve (AUC) was employed to identify the optimal model, which was then evaluated for assisting radiologists in the empirical and RADS groups in diagnosing LNM. Finally, the prediction process of the optimal model was visualized using SHAP plots.
resultsThe HR model demonstrated superior performance, achieving the highest AUC values of 0.876, 0.869, and 0.795 in the training, validation, and test cohorts, respectively. Regardless of seniority, the empirical group of radiologists showed a significant improvement in the AUC and accuracy when using the HR model, compared to working alone (p < 0.05). Furthermore, the RADS group radiologists exhibited strong reclassification ability, effectively reevaluating patients with false-negative LN initially classified as Node-RADS score 1 or 2 by themselves.
conclusionThe HR model facilitates the accurate prediction of LNM in AEG and holds potential as a valuable tool to augment radiologists' diagnostic capabilities in daily clinical practice. CRITICAL RELEVANCE STATEMENT: The habitat radiomics model could accurately predict the lymph node status of adenocarcinoma in the esophagogastric junction and assist radiologists in improving diagnostic efficacy, which lays the foundation for accurate staging and effective treatment. KEY POINTS: Accurate lymph node diagnosis in esophagogastric junction adenocarcinoma is beneficial for prognosis. Habitat radiomics model accurately predicted and assisted physicians in diagnosing lymph nodes. The habitat model effectively reclassified false-negative lymph nodes at Node-RADS 1 and 2.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.